Neuren Pharmaceuticals Ltd has released a press release.
Neuren approaching key milestones in Q4 2019
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- NNZ-2591 positive effects in Pitt Hopkins syndrome model
- NNZ-2591 positive effects in Angelman syndrome model
- Update on development plan for NNZ-2591
- Neurens Rett syndrome Phase 2 trial published in Neurology
- Preliminary Final Report and statutory accounts
Later from Neuren Pharmaceuticals
- FDA grants Orphan Drug Designation for NNZ-2591 in Angelman
- FDA grants Orphan for both Phelan-McDermid and Pitt Hopkins
- FDA Grants Orphan Drug Designation for Neuren's NNZ-2591 to Treat Angelman, Phelan-McDermid and Pitt Hopkins Syndromes
- Phase 3 trial of trofinetide in Rett syndrome commences
- Patent to 2034 granted in Europe for Neurens NNZ-2591
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals